[2P-0301] The Anticoagulant Nafamostat Potently Inhibits SARS-CoV-2 S Protein-Mediated Fusion in a Cell Fusion Assay System and Viral Infection in vitro in a Cell-Type-Dependent Manner

○Mizuki Yamamoto¹, Jun-ichiro Inoue^1,2, Yasushi Kawaguchi^1,3, Jin Gohda¹ (1.Research Center for Asian Infectious Diseases, The Institute of Medical Science, The University of Tokyo, 2.Senior Professor Office, The University of Tokyo, 3.Division of Molecular Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo)

SARS-CoV-2, nafamostat, cell fusion, dual split protein, novel coronavirus